2016 Press Releases

Keyword Search
 
DateTitle  
06-Dec-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – November 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Dec. 6, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
01-Dec-2016ERYTECH Presents New Data on GRASPA’s Mechanism of Action at ASH Annual Meeting
LYON, France--(BUSINESS WIRE)--Dec. 1, 2016-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the presentation of promising preliminary data for the Company's lead product candidate, eryaspase, also known as ERY-ASP or under the trade name ... 
 Printer Friendly Version
14-Nov-2016ERYTECH Announces Withdrawal of Its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission
Conference call and webcast scheduled for Tuesday, November 15th at 15:00 pm CET/9:00 am ET Withdrawal of European Marketing Authorization Application (MAA) for eryaspase (GRASPA®); additional data requested by the Committee for Human Medicinal Products (CHMP) will take more time to provide than allowed in the CHMP’s approval procedures Intention to resubmit the MAA mid-2017 LYON, Fran... 
 Printer Friendly Version
14-Nov-2016Erytech: Information related to total number of voting rights and shares composing the share capital – October 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Nov. 14, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com       ... 
 Printer Friendly Version
03-Nov-2016ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016
Conference call and webcast scheduled for Friday, November 4th at 15:00 pm CET/10:00 am EDT Ongoing review by European Medicines Agency (EMA) of Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of acute lymphoblastic leukemia (ALL); Completed enrollment of patients in Phase 2 studies of eryaspase in acute myeloid leukemia (AML) and pancreatic cancer; Strengthened executive management team and board of directors; Cash position of €30.4 million at ... 
 Printer Friendly Version
03-Nov-2016ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016
Conference call and webcast scheduled for Friday, November 4th at 15:00 pm CET/10:00 am EDT Ongoing review by European Medicines Agency (EMA) of Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of acute lymphoblastic leukemia (ALL); Completed enrollment of patients in Phase 2 studies of eryaspase in acute myeloid leukemia (AML) and pancreatic cancer; Str... 
 Printer Friendly Version
27-Oct-2016ERYTECH Strengthens Executive Leadership Team with Appointments of Chief Scientific Officer and Chief Business Officer
Dr. Alexander Scheer Joins Company as CSO and Jean-Sébastien Cleiftie as CBO LYON, France--(BUSINESS WIRE)--Oct. 27, 2016-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the appointments of Dr. Alexander Scheer, Ph.D.... 
 Printer Friendly Version
26-Oct-2016ERYTECH to Hold Q3 2016 Business Update Conference Call on November 4th, 2016
LYON, France--(BUSINESS WIRE)--Oct. 26, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended September 30, 2016 on Thursday, November 03... 
 Printer Friendly Version
06-Oct-2016Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - September 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Oct. 6, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting ri... 
 Printer Friendly Version
26-Sep-2016ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer
Primary data read-out from the trial expected by early 2017 LYON, France--(BUSINESS WIRE)--Sep. 26, 2016-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known a... 
 Printer Friendly Version
06-Sep-2016ERYTECH Reports Business and Financial Update for the First Half of 2016
Conference call and webcast scheduled for Wednesday, September 7th at 3:00 pm CET/9:00 am EDT Ongoing review by European Medicines Agency (EMA) of Marketing Authorization Application (MAA) for GRASPA for the treatment of acute lymphoblastic leukemia (ALL) Completed patient enrollment in Phase 2b study of eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) Enrollment of p... 
 Printer Friendly Version
05-Sep-2016ERYTECH Appoints Allene M. Diaz to its Board of Directors
LYON, France--(BUSINESS WIRE)--Sep. 5, 2016-- Regulatory News: ERYTECH Pharma (Euronext Paris:ERYP) (Paris:ERYP) (ADR:EYRYY), a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur). As censeur, Ms. Diaz will initially attend all Board of ... 
 Printer Friendly Version
01-Sep-2016Erytech : Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - August 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Sep. 1, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting ri... 
 Printer Friendly Version
30-Aug-2016ERYTECH to Hold Q2 2016 Business Update Conference Call on September 7th, 2016
LYON, France--(BUSINESS WIRE)--Aug. 30, 2016-- Regulatory News: ERYTECH (Euronext Paris: FR0011471135 - ERYP) (Paris:ERYP) (ADR:EYRYY), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended June 30, 2016 on Tuesday, September 06, 2... 
 Printer Friendly Version
29-Aug-2016ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia
Primary data read-out for the European trial expected in 2H2017 LYON, France--(BUSINESS WIRE)--Aug. 29, 2016-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it has reached full patient enrollment in the Phase 2b trial of eryaspas... 
 Printer Friendly Version
02-Aug-2016Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - July 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Aug. 2, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
11-Jul-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - June 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jul. 11, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
07-Jun-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - May 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jun. 7, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
10-May-2016ERYTECH Provides Business and Financial Highlights for First Quarter 2016
Conference call and webcast scheduled for Wednesday, May 11th at 15:00 CET/9:00 EDT European Medicines Agency (EMA) review of Marketing Authorization Application (MAA) for GRASPA for the treatment of acute lymphoblastic leukemia (ALL) is ongoing Solid cash position of €40.6 million at quarter-end LYON, France--(BUSINESS WIRE)--May 10, 2016-- Regulatory News: ERYTECH Pharma (Paris:E... 
 Printer Friendly Version
09-May-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - April 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--May 9, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
Download PDFPrinter Friendly Version
02-May-2016Erytech to Hold Q1 2016 Business Update Conference Call on May 11th, 2016
LYON, France--(BUSINESS WIRE)--May 2, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended March 31, 2016 on Tuesday, May 10, 2016 after... 
Download PDFPrinter Friendly Version
30-Apr-2016ERYTECH makes its 2015 Reference Document available
LYON, France--(BUSINESS WIRE)--Apr. 30, 2016-- Regulatory News: ERYTECH (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it had filed on April 29, 2016 with the “Autorité des Marchés Financiers (AMF)”, its 2015 Reference Document, including the management report and th... 
Download PDFPrinter Friendly Version
07-Apr-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - March 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Apr. 7, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
Download PDFPrinter Friendly Version
17-Mar-2016ERYTECH to Present Two Posters at AACR
LYON, France--(BUSINESS WIRE)--Mar. 17, 2016-- Regulatory News: ERYTECH (Euronext Paris: FR0011471135 - ERYP) (ADR:EYRYY), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20, 2016... 
Download PDFPrinter Friendly Version
15-Mar-2016ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS Immunotherapy Technology
LYON, France--(BUSINESS WIRE)--Mar. 15, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 12/... 
Download PDFPrinter Friendly Version
09-Mar-2016Erytech Pharma: Information related to total number of voting rights and shares composing the share capital - February 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Mar. 9, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
Download PDFPrinter Friendly Version
23-Feb-2016ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015
Conference call and webcast on Wednesday, February 24th at 15:00 pm CET/09:00 am EST GRASPA entered European MAA registration phase for treatment of patients with acute lymphoblastic leukemia (ALL) Further EU and US clinical development plans in ALL established Clinical programs in acute myeloid leukemia (AML) and pancreatic cancer on track €25.4 million raised in December... 
Download PDFPrinter Friendly Version
18-Feb-2016Erytech to Hold Full-year 2015 Business Update Conference Call on February 24, 2016
LYON, France--(BUSINESS WIRE)--Feb. 18, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the year ended December 31, 2015 on Tuesday, February 23, 201... 
Download PDFPrinter Friendly Version
08-Feb-2016Erytech Announces 2016 Financial Calendar
LYON, France--(BUSINESS WIRE)--Feb. 8, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today published its financial calendar for 2016: Fourth Quarter and Full-Year 2015 Financial Results and Business Upda... 
Download PDFPrinter Friendly Version
08-Feb-2016Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital January 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Feb. 8, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   Total of shares ... 
Download PDFPrinter Friendly Version
04-Feb-2016CORRECTING and REPLACING: Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital
December 2015 Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Feb. 4, 2016-- Regulatory News: This replaces the announcement made at 2:20 pm on January 12 due to the following corrections: The total of brut voting rights of 9 625 437 is supersedes by 9 706 437 and the total of net voting rights of 9 622 937 is supersedes by 9 703 937. ... 
Download PDFPrinter Friendly Version
03-Feb-2016Erytech to Present at Upcoming Investor Conferences
LYON, France--(BUSINESS WIRE)--Feb. 3, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that Gil Beyen, Chairman and Chief Executive Officer and Eric Soyer, Chief Financial Officer and Chief Operating Officer, will pr... 
Download PDFPrinter Friendly Version
12-Jan-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital
December 2015 Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jan. 12, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market : Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
Download PDFPrinter Friendly Version
11-Jan-2016ERYTECH Reports Financial Highlights for Q4 2015
Strong cash balance of €45.6 million LYON , France--(BUSINESS WIRE)--Jan. 11, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reports revenue and cash balance for the fourth quarter of 2015. As of December ... 
Download PDFPrinter Friendly Version
06-Jan-2016ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia
LYON, France--(BUSINESS WIRE)--Jan. 6, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB1) completed its third safety assessment of the company’s Phase 2b ENFOR... 
Download PDFPrinter Friendly Version
04-Jan-2016ERYTECH Announces Management Change
LYON, France--(BUSINESS WIRE)--Jan. 4, 2016-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that Yann Godfrin will be leaving the company to pursue new entrepreneurial projects. Yann Godfrin is one of ... 
Download PDFPrinter Friendly Version
Top